A Randomized Open-Label Phase 2b Study of Hepatic Infusions of Anti-CEA CAR-T Cells Alternating With Systemic Chemotherapy Versus Chemotherapy Alone In Patients With Liver Metastases Due To CEA-Expressing Pancreatic Adenocarcinoma
Sorrento Therapeutics, Inc. is exploring the use of Anti-CEA CAR-T cells in combination with systemic chemotherapy for patients with unresectable liver metastases from CEA-expressing pancreatic adenocarcinoma. The study aims to demonstrate improved efficacy and safety compared to chemotherapy alone. Given the high unmet medical need in pancreatic cancer, if successful, this therapy could capture significant market share, particularly as current treatment options are limited. The competitive landscape includes other CAR-T therapies and novel agents targeting pancreatic cancer, necessitating a robust differentiation strategy. The withdrawal of the trial may indicate challenges in recruitment or safety concerns, which could impact investor confidence and future funding opportunities.
Indication: Malignant Tumor of Pancreas Metastatic to Liver
Modality: small molecule
Target: CEA (Carcinoembryonic Antigen)
Sponsor: Sorrento Therapeutics, Inc.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CEA (Carcinoembryonic Antigen)
View original source fields
Condition raw: Malignant Tumor of Pancreas Metastatic to Liver
Condition normalized: Malignant Tumor of Pancreas Metastatic to Liver
Modality raw: small molecule
Modality normalized: small molecule
Target raw: CEA (Carcinoembryonic Antigen)
Target normalized: CEA (Carcinoembryonic Antigen)